# | Title | Journal | Year | Citations |
---|
1 | Epigenetic regulation of microRNA expression in colorectal cancer | International Journal of Cancer | 2009 | 418 |
2 | Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia | Blood | 2004 | 204 |
3 | Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia | Oncogene | 2005 | 202 |
4 | 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia | Blood | 2002 | 171 |
5 | Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia | British Journal of Cancer | 2004 | 101 |
6 | Epigenetic Signatures Associated with Different Levels of Differentiation Potential in Human Stem Cells | PLoS ONE | 2009 | 96 |
7 | Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia | European Journal of Cancer | 2009 | 76 |
8 | Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia | Leukemia Research | 2008 | 71 |
9 | Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms | Leukemia | 2005 | 68 |
10 | WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia | European Journal of Cancer | 2007 | 66 |
11 | CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia | Clinical Cancer Research | 2006 | 62 |
12 | Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes | Leukemia and Lymphoma | 2007 | 60 |
13 | The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3–4, is downregulated by hypermethylation in acute lymphoblastic leukemia | Leukemia | 2004 | 59 |
14 | Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia | Haematologica | 2007 | 54 |
15 | Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia | PLoS ONE | 2011 | 52 |
16 | Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome | Leukemia | 2006 | 46 |
17 | The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha | Haematologica | 2004 | 45 |
18 | Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia | Leukemia | 2012 | 41 |
19 | Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications | PLoS ONE | 2011 | 38 |
20 | Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant | Biology of Blood and Marrow Transplantation | 2019 | 34 |
21 | Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia‐positive acute lymphoblastic leukemia | Cancer Science | 2008 | 29 |
22 | Protein C, protein S and C4b-binding protein in neonatal severe infection and septic shock | Journal of Perinatal Medicine | 1992 | 21 |
23 | Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group | Leukemia and Lymphoma | 2021 | 21 |
24 | Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation | Haematologica | 2000 | 18 |
25 | Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia | Leukemia and Lymphoma | 2018 | 15 |
26 | Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group | American Journal of Transplantation | 2021 | 11 |
27 | Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study | Haematologica | 2022 | 11 |
28 | Passenger Lymphocyte Syndrome After Simultaneous Pancreas-Kidney Transplantation: A Case Report of an Unusual Cause of Alloimmune Hemolytic Anemia | Transplantation Proceedings | 2015 | 8 |
29 | The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial | Cancers | 2021 | 7 |
30 | Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers | Transplantation and Cellular Therapy | 2021 | 5 |
31 | Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft‐versus‐host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group | Transplant Infectious Disease | 2021 | 5 |
32 | Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry | Cancers | 2022 | 4 |
33 | microRNA Methylation Profile Has Prognosis Impact in Acute Lymphoblastic Leukemia Patients Undergoing Stem Cell Transplantation | Biology of Blood and Marrow Transplantation | 2011 | 3 |
34 | Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment | Bone Marrow Transplantation | 2021 | 3 |
35 | Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD | Therapeutic Advances in Hematology | 2022 | 2 |
36 | Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation | European Journal of Haematology | 2011 | 1 |
37 | Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH) | Blood | 2018 | 1 |
38 | Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC | Blood | 2021 | 1 |
39 | Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation | Transplantation and Cellular Therapy | 2022 | 1 |
40 | Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse? | Cancers | 2023 | 1 |
41 | Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia | Blood | 2016 | 0 |
42 | Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime | Blood | 2019 | 0 |
43 | No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group | Disease Markers | 2022 | 0 |